Positive results for NPS Pharmaceuticals' (Nasdaq:NPSP) Gattex resulted in shares of the company soaring over 30 percent.
Gattex treats patients with short bowel syndrome, which reduces the amount of intravenous nutrition needed by patients with the condition. NPS specializes in therapeutics for gastrointestinal and endocrine disorders.
The late-stage study was successful, driving the share price of NPSP up.
NPS Pharmaceuticals closed Monday at $10.01, gaining $2.39, or 31.47 percent.
No comments:
Post a Comment